Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 1 Demographic and clinical characteristics of study participants

From: Serum NR1 and NR2 concentrations in first-episode schizophrenia and clinical high-risk for psychosis

 

FES

CHR

HC

F/t

P

Subjects, n

41

34

41

Age, y

24.29 ± 5.87

21.41 ± 5.51

26.66 ± 6.30

7.29

0.001

Education, y

14.27 ± 4.56

12.97 ± 2.63

12.51 ± 3.33

2.53

0.08

Duration of illness, mo

27.86 ± 27.45

Age at onset

22.22 ± 5.71

SIPS-Positive

9.00 ± 3.44

0.34 ± 1.30

14.83

 < 0.001

SIPS-Negative

7.84 ± 5.16

0.17 ± 0.70

9.43

 < 0.001

SIPS-Disorganization

4.23 ± 2.63

0.07 ± 0.35

10.02

 < 0.001

SIPS-General

5.39 ± 2.88

0.12 ± 0.51

11.48

 < 0.001

SIPS-Total

26.45 ± 10.56

0.71 ± 2.77

14.97

 < 0.001

PANSS-Positive

24.25 ± 5.44

PANSS-Negative

20.03 ± 8.05

PANSS-general psychopathology

43.16 ± 6.03

PANSS-Total

87.87 ± 13.52

    

χ2

P

Men, n (%)

17 (41.46)

21 (61.76)

27 (65.85)

5.59

0.06

Married, n (%)

8 (19.51)

4 (11.76)

15 (36.59)

6.91

0.03

Family history, n (%)

8 (19.51)

11 (32.35)

1.62

0.20

Smoking, n (%)

3 (7.32)

2 (5.88)

6 (14.63)

2.00

0.37

Medication, n (%)

33 (80.49)

19 (55.88)

 Unmedicated

8 (19.51)

15 (44.12)

 AP

29 (70.73)

11 (32.35)

 AD

0

2 (5.88)

 AD + AP

0

4 (11.77)

 Unspecified

4 (9.76)

2 (5.88)

  1. AD Antidepressant, AP Antipsychotic